About Healx
Healx is a biotechnology company pioneering the use of artificial intelligence to accelerate drug discovery for rare diseases. Founded with the mission to bring treatments to the 95% of rare diseases that currently have no approved therapies, Healx has developed a proprietary AI-driven platform that combines machine learning algorithms with diverse biomedical data sources to identify promising drug candidates. The company's approach focuses on drug repurposing, leveraging existing compounds to reduce development timelines and costs while improving the probability of success. Healx's technology platform integrates multiple data types including genomic information, clinical data, scientific literature, and molecular databases to generate novel insights into disease mechanisms and potential therapeutic interventions. By applying advanced computational methods to rare disease research, Healx aims to transform the drug development landscape for underserved patient populations. The company works with pharmaceutical partners, patient advocacy groups, and research institutions to advance its pipeline of rare disease treatments from discovery through clinical development.
Clinical Focus
Medical conditions and clinical areas addressed by Healx.
Who It Serves
Social & Media
Follow on
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.